[
  {
    "ts": null,
    "headline": "Evaluating Eli Lilly (LLY) Valuation As GLP‑1 Growth Drives Strong Multiyear Shareholder Returns",
    "summary": "Eli Lilly (LLY) is back in focus after recent trading put its market performance under the microscope, as investors weigh its current valuation against multiyear total returns and the company’s large pharmaceutical portfolio. See our latest analysis for Eli Lilly. At a share price of $1,080.36, Eli Lilly’s 30 day share price return of 6.93% and 90 day share price return of 28.06% sit alongside a 1 year total shareholder return of 42.26% and a very large 5 year total shareholder return. This...",
    "url": "https://finnhub.io/api/news?id=d4a27c7caf84555caa689e5d585775f92f1ca17fd76048afb2faa8f9ba499ef0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767654718,
      "headline": "Evaluating Eli Lilly (LLY) Valuation As GLP‑1 Growth Drives Strong Multiyear Shareholder Returns",
      "id": 137997662,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly (LLY) is back in focus after recent trading put its market performance under the microscope, as investors weigh its current valuation against multiyear total returns and the company’s large pharmaceutical portfolio. See our latest analysis for Eli Lilly. At a share price of $1,080.36, Eli Lilly’s 30 day share price return of 6.93% and 90 day share price return of 28.06% sit alongside a 1 year total shareholder return of 42.26% and a very large 5 year total shareholder return. This...",
      "url": "https://finnhub.io/api/news?id=d4a27c7caf84555caa689e5d585775f92f1ca17fd76048afb2faa8f9ba499ef0"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly (LLY) Stock Drops Despite Market Gains: Important Facts to Note",
    "summary": "Eli Lilly (LLY) reached $1 at the closing of the latest trading day, reflecting a -3.6% change compared to its last close.",
    "url": "https://finnhub.io/api/news?id=093dd38097933ccf0621a034206d00e050b66731e6218dba7f94af76f8896ea2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767653103,
      "headline": "Eli Lilly (LLY) Stock Drops Despite Market Gains: Important Facts to Note",
      "id": 137997663,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly (LLY) reached $1 at the closing of the latest trading day, reflecting a -3.6% change compared to its last close.",
      "url": "https://finnhub.io/api/news?id=093dd38097933ccf0621a034206d00e050b66731e6218dba7f94af76f8896ea2"
    }
  },
  {
    "ts": null,
    "headline": "Stocks to Watch Recap: Chevron, Versant, Bed Bath, AMD",
    "summary": "↗️ Trump Media (DJT): Shares in President Trump's social-media company rose 4.5% Monday. The U.S. ousted Venezuelan President Nicolás Maduro over the weekend and Trump pledged to dispatch U.S. drillers to revive Venezuela's crude output.",
    "url": "https://finnhub.io/api/news?id=acf09dfbfc2da1c4ad9e7c4857d7d645efc92ad56c425a5d7e9d0b2925aa1bdc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767648768,
      "headline": "Stocks to Watch Recap: Chevron, Versant, Bed Bath, AMD",
      "id": 137997664,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "↗️ Trump Media (DJT): Shares in President Trump's social-media company rose 4.5% Monday. The U.S. ousted Venezuelan President Nicolás Maduro over the weekend and Trump pledged to dispatch U.S. drillers to revive Venezuela's crude output.",
      "url": "https://finnhub.io/api/news?id=acf09dfbfc2da1c4ad9e7c4857d7d645efc92ad56c425a5d7e9d0b2925aa1bdc"
    }
  },
  {
    "ts": null,
    "headline": "Sector Update: Health Care Stocks Decline Late Afternoon",
    "summary": "Health care stocks were lower late Monday afternoon, with the NYSE Health Care Index easing 0.1% and",
    "url": "https://finnhub.io/api/news?id=eb7e5a1cde3919b616eea27253995021ee5222af89d5ff853445ac3209bf61bd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767647097,
      "headline": "Sector Update: Health Care Stocks Decline Late Afternoon",
      "id": 137997665,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Health care stocks were lower late Monday afternoon, with the NYSE Health Care Index easing 0.1% and",
      "url": "https://finnhub.io/api/news?id=eb7e5a1cde3919b616eea27253995021ee5222af89d5ff853445ac3209bf61bd"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk Rolls Out Wegovy's Weight Loss Pill in US",
    "summary": "Novo Nordisk (NVO) said Monday that its Wegovy pill, the first oral medicine for obesity in the US,",
    "url": "https://finnhub.io/api/news?id=3a2a42854be48f78573d8907b87d6d08f5f340c5ac179a85fa3ac80f9bf79ba1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767640152,
      "headline": "Novo Nordisk Rolls Out Wegovy's Weight Loss Pill in US",
      "id": 137997666,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Novo Nordisk (NVO) said Monday that its Wegovy pill, the first oral medicine for obesity in the US,",
      "url": "https://finnhub.io/api/news?id=3a2a42854be48f78573d8907b87d6d08f5f340c5ac179a85fa3ac80f9bf79ba1"
    }
  },
  {
    "ts": null,
    "headline": "Biotech and Pharma Stocks Tumble as Investors Race into Energy",
    "summary": "Cash has flowed into oil stocks following the U.S.’s seizing of Venezuelan President Nicolás Maduro.",
    "url": "https://finnhub.io/api/news?id=28a81daf1c3ad74136be78f734ee45654c1db7bb4e799156d35e55a1db347bb4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767639120,
      "headline": "Biotech and Pharma Stocks Tumble as Investors Race into Energy",
      "id": 137997667,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Cash has flowed into oil stocks following the U.S.’s seizing of Venezuelan President Nicolás Maduro.",
      "url": "https://finnhub.io/api/news?id=28a81daf1c3ad74136be78f734ee45654c1db7bb4e799156d35e55a1db347bb4"
    }
  },
  {
    "ts": null,
    "headline": "Google, Nvidia, Reddit — And This Hot IPO — Lead Slew Of Stocks To Watch",
    "summary": "As GE Aerospace soars and Google stock sets up, a barrage of top names on the IBD Leaderboard come into focus.",
    "url": "https://finnhub.io/api/news?id=2620d8c2c57703bab4bd7086e42864a1fbfe0ae6529badeba9525b94c5109168",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767636551,
      "headline": "Google, Nvidia, Reddit — And This Hot IPO — Lead Slew Of Stocks To Watch",
      "id": 137993223,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "As GE Aerospace soars and Google stock sets up, a barrage of top names on the IBD Leaderboard come into focus.",
      "url": "https://finnhub.io/api/news?id=2620d8c2c57703bab4bd7086e42864a1fbfe0ae6529badeba9525b94c5109168"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Lags In The Weight-Loss Pill War. But It Has A Plan.",
    "summary": "Eli Lilly stock is falling as rival Novo Nordisk hit a milestone in the area of weight-loss drugs. But Lilly has a rival drug in the pipeline.",
    "url": "https://finnhub.io/api/news?id=3c4da6cbb3c82254c3586017832f3276757dc3d1893f474d202254eb65b3eea4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767636441,
      "headline": "Eli Lilly Lags In The Weight-Loss Pill War. But It Has A Plan.",
      "id": 137993616,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly stock is falling as rival Novo Nordisk hit a milestone in the area of weight-loss drugs. But Lilly has a rival drug in the pipeline.",
      "url": "https://finnhub.io/api/news?id=3c4da6cbb3c82254c3586017832f3276757dc3d1893f474d202254eb65b3eea4"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Lags In The Weight Loss Pill War. But It Has A Plan.",
    "summary": "Eli Lilly stock is falling as rival Novo Nordisk hit a milestone in the area of weight loss drugs. But Lilly has a rival drug in the pipeline.",
    "url": "https://finnhub.io/api/news?id=0f2b1925ceb1579c156372d041658982f1caddb7fb06e83310d9a22feb6f1827",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767636441,
      "headline": "Eli Lilly Lags In The Weight Loss Pill War. But It Has A Plan.",
      "id": 137993269,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly stock is falling as rival Novo Nordisk hit a milestone in the area of weight loss drugs. But Lilly has a rival drug in the pipeline.",
      "url": "https://finnhub.io/api/news?id=0f2b1925ceb1579c156372d041658982f1caddb7fb06e83310d9a22feb6f1827"
    }
  },
  {
    "ts": null,
    "headline": "3 Reasons Why Lilly (LLY) Is a Great Growth Stock",
    "summary": "Lilly (LLY) possesses solid growth attributes, which could help it handily outperform the market.",
    "url": "https://finnhub.io/api/news?id=fd73b1280070434af0238f5fa429d91be01018e37d87b10ca88b02bca1af0d54",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767635105,
      "headline": "3 Reasons Why Lilly (LLY) Is a Great Growth Stock",
      "id": 137997668,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Lilly (LLY) possesses solid growth attributes, which could help it handily outperform the market.",
      "url": "https://finnhub.io/api/news?id=fd73b1280070434af0238f5fa429d91be01018e37d87b10ca88b02bca1af0d54"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk Stock Rises as Wegovy Pill Hits the U.S. Market",
    "summary": "Novo Nordisk's New Wegovy Pill Tests the Limits of Demand",
    "url": "https://finnhub.io/api/news?id=d3f3f232f371b80641396aef9e01850191a50f95f9af2ed35e5eefece885b95b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767634085,
      "headline": "Novo Nordisk Stock Rises as Wegovy Pill Hits the U.S. Market",
      "id": 137993270,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Novo Nordisk's New Wegovy Pill Tests the Limits of Demand",
      "url": "https://finnhub.io/api/news?id=d3f3f232f371b80641396aef9e01850191a50f95f9af2ed35e5eefece885b95b"
    }
  },
  {
    "ts": null,
    "headline": "3 Top Ranked Stocks to Buy for 2026 (LLY, WFRD, PGY)",
    "summary": "Eli Lilly, Pagaya Technologies Ltd. and Weatherford International stocks all boast numerous bullish tailwinds heading into this new year.",
    "url": "https://finnhub.io/api/news?id=a85bc890d0f9fad746d6990cd8e07e41fee58ca079244ea3757a0b94375f5edc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767632220,
      "headline": "3 Top Ranked Stocks to Buy for 2026 (LLY, WFRD, PGY)",
      "id": 137993600,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly, Pagaya Technologies Ltd. and Weatherford International stocks all boast numerous bullish tailwinds heading into this new year.",
      "url": "https://finnhub.io/api/news?id=a85bc890d0f9fad746d6990cd8e07e41fee58ca079244ea3757a0b94375f5edc"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk’s Wegovy Pill Hits Pharmacies. It’s the Latest Move in the Weight-Loss Showdown.",
    "summary": "The company appears to have gotten the jump on Eli Lilly with what could be an important evolution in the market.",
    "url": "https://finnhub.io/api/news?id=6260a0efcd2f6a72f3151b64d8cb33291eaa05cc741bd498fefc4f5ea9e2a566",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767632040,
      "headline": "Novo Nordisk’s Wegovy Pill Hits Pharmacies. It’s the Latest Move in the Weight-Loss Showdown.",
      "id": 137993271,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The company appears to have gotten the jump on Eli Lilly with what could be an important evolution in the market.",
      "url": "https://finnhub.io/api/news?id=6260a0efcd2f6a72f3151b64d8cb33291eaa05cc741bd498fefc4f5ea9e2a566"
    }
  },
  {
    "ts": null,
    "headline": "LLY Up 28% in 3 Months: Is it the Right Time to Invest in the Stock?",
    "summary": "LLY has surged 28% in three months, driven by blockbuster GLP-1 drugs, its $1T market cap and a deep obesity pipeline.",
    "url": "https://finnhub.io/api/news?id=1ffea0e80a2e3fe4feff2289c2341ebf9c13d455587f2f170a6e06839a070a96",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767627420,
      "headline": "LLY Up 28% in 3 Months: Is it the Right Time to Invest in the Stock?",
      "id": 137992405,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "LLY has surged 28% in three months, driven by blockbuster GLP-1 drugs, its $1T market cap and a deep obesity pipeline.",
      "url": "https://finnhub.io/api/news?id=1ffea0e80a2e3fe4feff2289c2341ebf9c13d455587f2f170a6e06839a070a96"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk Stock Rises on Launch of Weight-Loss Pills",
    "summary": "Novo Nordisk’s shares rallied after the drugmaker said its new Wegovy weight-loss pill is now broadly available in the U.S., following regulatory approval last month.  The Wegovy product is the first GLP-1 pill approved specifically for weight loss.  It will tap into what analysts expect will be substantial demand from consumers seeking an alternative to the injections that have dominated the anti-obesity market to date.",
    "url": "https://finnhub.io/api/news?id=dffa7aade06eeb5490fe1e2917ff9d8e279e6822f7a378eb3abf08dad9ee2a31",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767625045,
      "headline": "Novo Nordisk Stock Rises on Launch of Weight-Loss Pills",
      "id": 137991006,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Novo Nordisk’s shares rallied after the drugmaker said its new Wegovy weight-loss pill is now broadly available in the U.S., following regulatory approval last month.  The Wegovy product is the first GLP-1 pill approved specifically for weight loss.  It will tap into what analysts expect will be substantial demand from consumers seeking an alternative to the injections that have dominated the anti-obesity market to date.",
      "url": "https://finnhub.io/api/news?id=dffa7aade06eeb5490fe1e2917ff9d8e279e6822f7a378eb3abf08dad9ee2a31"
    }
  },
  {
    "ts": null,
    "headline": "Wall Street Analysts Think Lilly (LLY) Is a Good Investment: Is It?",
    "summary": "According to the average brokerage recommendation (ABR), one should invest in Lilly (LLY). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?",
    "url": "https://finnhub.io/api/news?id=8de7b0e4af466d31d24a5a1be031d914379116213564ee51b08989f985b7a451",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767624602,
      "headline": "Wall Street Analysts Think Lilly (LLY) Is a Good Investment: Is It?",
      "id": 137992406,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "According to the average brokerage recommendation (ABR), one should invest in Lilly (LLY). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?",
      "url": "https://finnhub.io/api/news?id=8de7b0e4af466d31d24a5a1be031d914379116213564ee51b08989f985b7a451"
    }
  },
  {
    "ts": null,
    "headline": "Is It Time to Dump Your Shares of Eli Lilly?",
    "summary": "Eli Lilly has the lead in the GLP-1 race, but Novo Nordisk just changed the game.",
    "url": "https://finnhub.io/api/news?id=6a14e106f706aa55814ec6cf8b4b6598b094364c9c0d68a3b1572eaa7a7ae725",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767622800,
      "headline": "Is It Time to Dump Your Shares of Eli Lilly?",
      "id": 137991007,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly has the lead in the GLP-1 race, but Novo Nordisk just changed the game.",
      "url": "https://finnhub.io/api/news?id=6a14e106f706aa55814ec6cf8b4b6598b094364c9c0d68a3b1572eaa7a7ae725"
    }
  },
  {
    "ts": null,
    "headline": "AI took investors on a date in 2025. In 2026, analysts say it's time to foot the bill.",
    "summary": "As the AI trade becomes \"fractured,\" 2026 could see other stocks finally outshine the \"Magnificent Seven.\"",
    "url": "https://finnhub.io/api/news?id=8bc5645a656abb8f8ecdca3b915a1c7c67b2fa5e37d8aa133dbeb5a3e90263f8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767621612,
      "headline": "AI took investors on a date in 2025. In 2026, analysts say it's time to foot the bill.",
      "id": 137990801,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "As the AI trade becomes \"fractured,\" 2026 could see other stocks finally outshine the \"Magnificent Seven.\"",
      "url": "https://finnhub.io/api/news?id=8bc5645a656abb8f8ecdca3b915a1c7c67b2fa5e37d8aa133dbeb5a3e90263f8"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk’s Wegovy Pill Now Broadly Available Across U.S.",
    "summary": "Novo Nordisk’s Wegovy weight-loss pill is now broadly available across the U.S., two weeks after it received U.S. regulatory approval, the Danish drugmaker said.",
    "url": "https://finnhub.io/api/news?id=61433101f8fa8bd08dee976022d0f31a87c11bcfbf256baecfae6f168bee88d0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767620520,
      "headline": "Novo Nordisk’s Wegovy Pill Now Broadly Available Across U.S.",
      "id": 137991009,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Novo Nordisk’s Wegovy weight-loss pill is now broadly available across the U.S., two weeks after it received U.S. regulatory approval, the Danish drugmaker said.",
      "url": "https://finnhub.io/api/news?id=61433101f8fa8bd08dee976022d0f31a87c11bcfbf256baecfae6f168bee88d0"
    }
  },
  {
    "ts": null,
    "headline": "Will NVO's Wegovy Pill Approval for Obesity be a Game Changer in 2026?",
    "summary": "Novo Nordisk's FDA-approved Wegovy pill marks the first oral GLP-1 weight loss therapy, aiming to revive momentum and reshape competition in 2026.",
    "url": "https://finnhub.io/api/news?id=d41cbbbaa79aec18212cc5bdf8f5ab1c7bcebf2fdf9382b79b54582758a57e76",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767620040,
      "headline": "Will NVO's Wegovy Pill Approval for Obesity be a Game Changer in 2026?",
      "id": 137991010,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Novo Nordisk's FDA-approved Wegovy pill marks the first oral GLP-1 weight loss therapy, aiming to revive momentum and reshape competition in 2026.",
      "url": "https://finnhub.io/api/news?id=d41cbbbaa79aec18212cc5bdf8f5ab1c7bcebf2fdf9382b79b54582758a57e76"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk launches US price war over weight-loss pills",
    "summary": "Novo Nordisk is launching a weight-loss pill price war as it seeks to keep pace with arch-rival Eli Lilly in the market for GLP-1 drugs. The...",
    "url": "https://finnhub.io/api/news?id=90fef0b41e04fcb06abf640906e95fe0cfe31b0777ba9176ad87167f730d394c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767619673,
      "headline": "Novo Nordisk launches US price war over weight-loss pills",
      "id": 137993272,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Novo Nordisk is launching a weight-loss pill price war as it seeks to keep pace with arch-rival Eli Lilly in the market for GLP-1 drugs. The...",
      "url": "https://finnhub.io/api/news?id=90fef0b41e04fcb06abf640906e95fe0cfe31b0777ba9176ad87167f730d394c"
    }
  },
  {
    "ts": null,
    "headline": "Watch 5 AI-Powered Medical Stocks for a Strong Portfolio in 2026",
    "summary": "LLY, MDT, ISRG, REGN and JNJ are five defensive medical stocks using AI to drive growth, diagnostics and innovation into 2026.",
    "url": "https://finnhub.io/api/news?id=ddde3dcd0e8529711e9d3c3e823924926f92591dbcaf392e5c937520730cc7fb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767616860,
      "headline": "Watch 5 AI-Powered Medical Stocks for a Strong Portfolio in 2026",
      "id": 137991011,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "LLY, MDT, ISRG, REGN and JNJ are five defensive medical stocks using AI to drive growth, diagnostics and innovation into 2026.",
      "url": "https://finnhub.io/api/news?id=ddde3dcd0e8529711e9d3c3e823924926f92591dbcaf392e5c937520730cc7fb"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk launches Wegovy pill to US self-pay patients",
    "summary": "STORY: Novo Nordisk is due to launch its once-daily Wegovy weightloss pill in the U.S. from Monday (January 5).The Danish drugmaker said it will offer 1.5 and 4 milligram pills at $149 per month to self-paying patients.The U.S. Food and Drug Administration approved the pill last month.It was a major boost for Novo as it tries to regain lost ground from U.S. rival Eli Lilly.It offers a more flexible regime and an alternative for those who don't like needles used in injectable medication.The launch could be a positive step for a company which saw profit warnings and sliding shares through last year.The semaglutide pills contain the same active ingredient as injectable Wegovy and Ozempic.The weight-loss pill version will also be a test case for the fast-growing cash-paying consumer market.A key part of making it a success will be attracting cash-paying consumers who can't get insurance coverage.That's a big shift from a business model where drug pricing is managed through health insurance plans, which has dominated for decades.Novo also said the pill will be sold in 9 mg and a higher long-term dose of 25 mg, which will cost nearly $300 per month.",
    "url": "https://finnhub.io/api/news?id=f9cc4e8165f20cf6a2867ac3d9951d97b77776395e9cb0896971e5eb17b4bc54",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767616576,
      "headline": "Novo Nordisk launches Wegovy pill to US self-pay patients",
      "id": 137991012,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "STORY: Novo Nordisk is due to launch its once-daily Wegovy weightloss pill in the U.S. from Monday (January 5).The Danish drugmaker said it will offer 1.5 and 4 milligram pills at $149 per month to self-paying patients.The U.S. Food and Drug Administration approved the pill last month.It was a major boost for Novo as it tries to regain lost ground from U.S. rival Eli Lilly.It offers a more flexible regime and an alternative for those who don't like needles used in injectable medication.The launch could be a positive step for a company which saw profit warnings and sliding shares through last year.The semaglutide pills contain the same active ingredient as injectable Wegovy and Ozempic.The weight-loss pill version will also be a test case for the fast-growing cash-paying consumer market.A key part of making it a success will be attracting cash-paying consumers who can't get insurance coverage.That's a big shift from a business model where drug pricing is managed through health insurance plans, which has dominated for decades.Novo also said the pill will be sold in 9 mg and a higher long-term dose of 25 mg, which will cost nearly $300 per month.",
      "url": "https://finnhub.io/api/news?id=f9cc4e8165f20cf6a2867ac3d9951d97b77776395e9cb0896971e5eb17b4bc54"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk to Sell Wegovy Pill in U.S. Starting at $149 per Month",
    "summary": "Launch targets self-pay market as company expands weight-loss portfolio",
    "url": "https://finnhub.io/api/news?id=9a68ee5688e675d2c9a96fbe78a1ed5c4a233e2a003f706f894ccf9e4a9daf89",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767614866,
      "headline": "Novo Nordisk to Sell Wegovy Pill in U.S. Starting at $149 per Month",
      "id": 137991013,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Launch targets self-pay market as company expands weight-loss portfolio",
      "url": "https://finnhub.io/api/news?id=9a68ee5688e675d2c9a96fbe78a1ed5c4a233e2a003f706f894ccf9e4a9daf89"
    }
  },
  {
    "ts": null,
    "headline": "China Market Unsettled, But Novo Nordisk's Oral Wegovy May Keep Revenue On Track",
    "summary": "Novo Nordisk A/S launches oral Wegovy in the U.S. with aggressive pricing as China patent expiry looms. Click for this updated look at NVO stock prospects.",
    "url": "https://finnhub.io/api/news?id=e1166e1b307f631abe680d11b9f566894880c0695f73ed9995d5dcb379c7363c",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767612661,
      "headline": "China Market Unsettled, But Novo Nordisk's Oral Wegovy May Keep Revenue On Track",
      "id": 137992137,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2239696011/image_2239696011.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Novo Nordisk A/S launches oral Wegovy in the U.S. with aggressive pricing as China patent expiry looms. Click for this updated look at NVO stock prospects.",
      "url": "https://finnhub.io/api/news?id=e1166e1b307f631abe680d11b9f566894880c0695f73ed9995d5dcb379c7363c"
    }
  },
  {
    "ts": null,
    "headline": "I Expect Novo Nordisk To Outperform Eli Lilly In 2026: Here's Why",
    "summary": "Novo Nordisk A/S rated Buy: FDA oral Wegovy, solid fundamentals, and low P/E vs. Eli Lilly. Click for this updated look at NVO stock prospects as compared to LLY.",
    "url": "https://finnhub.io/api/news?id=a2772918ca6b8a5afbaba41f05627c21b5916bac0b647324335ae83108b95366",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767606832,
      "headline": "I Expect Novo Nordisk To Outperform Eli Lilly In 2026: Here's Why",
      "id": 137990625,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2158305436/image_2158305436.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Novo Nordisk A/S rated Buy: FDA oral Wegovy, solid fundamentals, and low P/E vs. Eli Lilly. Click for this updated look at NVO stock prospects as compared to LLY.",
      "url": "https://finnhub.io/api/news?id=a2772918ca6b8a5afbaba41f05627c21b5916bac0b647324335ae83108b95366"
    }
  },
  {
    "ts": null,
    "headline": "Sterility Testing Market to Reach US$ 3,913.35 Million by 2035 Amid Rising Global Clinical Trial Activity Says Astute Analytica",
    "summary": "Robust expansion currently defines the landscape as major players like Eli Lilly and Merck aggressively fund new manufacturing facilities. Concurrently, the industry embraces rapid technological advancements in automated membrane filtration to streamline critical quality assurance processes.Chicago, Jan. 05, 2026 (GLOBE NEWSWIRE) -- The global sterility testing market was valued at US$ 1,344.31 million in 2025 and is expected to reach US$ 3,913.35 million by 2035, growing at a CAGR of 11.36% dur",
    "url": "https://finnhub.io/api/news?id=3ebf6c2c964e3b56c2ee198293a841431e74119e2bd0324ce94bd5751fa1948d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767601800,
      "headline": "Sterility Testing Market to Reach US$ 3,913.35 Million by 2035 Amid Rising Global Clinical Trial Activity Says Astute Analytica",
      "id": 137991014,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Robust expansion currently defines the landscape as major players like Eli Lilly and Merck aggressively fund new manufacturing facilities. Concurrently, the industry embraces rapid technological advancements in automated membrane filtration to streamline critical quality assurance processes.Chicago, Jan. 05, 2026 (GLOBE NEWSWIRE) -- The global sterility testing market was valued at US$ 1,344.31 million in 2025 and is expected to reach US$ 3,913.35 million by 2035, growing at a CAGR of 11.36% dur",
      "url": "https://finnhub.io/api/news?id=3ebf6c2c964e3b56c2ee198293a841431e74119e2bd0324ce94bd5751fa1948d"
    }
  },
  {
    "ts": null,
    "headline": "First GLP-1 pill for obesity from Novo Nordisk launches in the U.S.",
    "summary": "The drug's cash prices are among the lowest on the market, ranging from $149 to $299 per month, depending on the dose.",
    "url": "https://finnhub.io/api/news?id=41d5018d51222f453ae6b6e610dcfa530288df891e6c290e9b55a713672adbc2",
    "source": "CNBC",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767600007,
      "headline": "First GLP-1 pill for obesity from Novo Nordisk launches in the U.S. ",
      "id": 137992675,
      "image": "https://image.cnbcfm.com/api/v1/image/108231180-17640121262025-11-24t185244z_352081195_rc263iank3kr_rtrmadp_0_novo-nordisk.jpeg?v=1765918401&w=1920&h=1080",
      "related": "LLY",
      "source": "CNBC",
      "summary": "The drug's cash prices are among the lowest on the market, ranging from $149 to $299 per month, depending on the dose. ",
      "url": "https://finnhub.io/api/news?id=41d5018d51222f453ae6b6e610dcfa530288df891e6c290e9b55a713672adbc2"
    }
  },
  {
    "ts": null,
    "headline": "2 Unpopular Stocks That Deserve Some Love and 1 That Underwhelm",
    "summary": "Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad things about a company because it can jeopardize their other revenue-generating business lines like M&A advisory.",
    "url": "https://finnhub.io/api/news?id=81bcaf3e5d52c2398433cc0ea7795e1dd71526695dddd6a1a6af21f9fe440d90",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767587877,
      "headline": "2 Unpopular Stocks That Deserve Some Love and 1 That Underwhelm",
      "id": 137991015,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad things about a company because it can jeopardize their other revenue-generating business lines like M&A advisory.",
      "url": "https://finnhub.io/api/news?id=81bcaf3e5d52c2398433cc0ea7795e1dd71526695dddd6a1a6af21f9fe440d90"
    }
  }
]